MNX1 and prostate cancer: MNX1-AS1 has previously attracted the attention of researchers with different studies showing it is overexpressed in a variety of malignancies including colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, breast cancer, esophageal cancer (ESCC), laryngeal squamous cell carcinoma (LSCC), lung cancer, gall bladder cancer (GBC), hepatocellular carcinoma and intrahepatic cholangiocarcinoma [19–26, 31–34].